Promising drug combo targets aggressive brain cancers
NCT ID NCT00268385
First seen Mar 02, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This early-stage study tested the safety and best dose of a drug called vorinostat when given with the chemotherapy temozolomide for people with malignant gliomas, a type of aggressive brain cancer. The goal was to see if the combination could kill more tumor cells by making them more sensitive to treatment. The study involved 83 adults with recurrent brain tumors and focused on finding the safest dose and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
National Cancer Institute Neuro-Oncology Branch
Bethesda, Maryland, 20892, United States
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.